Publicacions (43) Publicacions de ALICIA PILAR HERRERO AMBROSIO

filter_list

2025

  1. OrPhar-SEFH 2024–2027 Strategic Plan

    Farmacia Hospitalaria, Vol. 49, Núm. 4, pp. 243-251

  2. Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast

    Journal of Oncology Pharmacy Practice, Vol. 31, Núm. 5, pp. 795-802

2024

  1. Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes

    Journal of Healthcare Quality Research, Vol. 39, Núm. 1, pp. 13-22

  2. Training program in compounding for pharmacy technicians through a digital platform and simulation techniques

    Farmacia Hospitalaria, Vol. 48, Núm. 3, pp. 93-100

2023

  1. Development of a telematic pharmaceutical care app (Haemoassist) for multidisciplinary follow-up of patients with congenital coagulopathies

    Expert Review of Hematology, Vol. 16, Núm. 3, pp. 213-226

  2. Green hospital pharmacy: A sustainable approach to the medication use process in a tertiary hospital

    Farmacia Hospitalaria, Vol. 47, Núm. 5, pp. T196-T200

  3. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation

    Clinical Drug Investigation, Vol. 43, Núm. 7, pp. 517-527

  4. Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 7, pp. 1793-1796

2022

  1. Influence of statin treatment in a cohort of patients admitted for COVID-19

    Medicina Clinica, Vol. 158, Núm. 12, pp. 586-595

2021

  1. Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients beyond the Indication of Clinical Trials: 48 Weeks' Results

    AIDS Research and Human Retroviruses, Vol. 37, Núm. 10, pp. 761-767

  2. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 893-899

  3. Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 5, pp. 268-272

2019

  1. Defibrotide for the treatment of severe hepatic sinusoidal obstruction syndrome: A single-centre experience

    European Journal of Hospital Pharmacy , Vol. 26, Núm. 6, pp. 343-346

2017

  1. Perception survey on the value of the hospital pharmacist at the emergency department

    Farmacia Hospitalaria, Vol. 41, Núm. 3, pp. 357-370

2016

  1. Analysis of an electronic medication reconciliation and information at discharge programme for frail elderly patients

    International Journal of Clinical Pharmacy, Vol. 38, Núm. 4, pp. 996-1001

  2. Juego de patentes. Sobre medicamentos genéricos y biosimilares

    Revista de calidad asistencial, Vol. 31, Núm. 2, pp. 99-105

  3. Objective quantification of adherence to prophylaxis in haemophilia patients aged 12 to 25 years and its potential association with bleeding episodes

    Thrombosis Research, Vol. 143, pp. 22-27

2015

  1. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

    Rheumatology (United Kingdom), Vol. 54, Núm. 7, pp. 1200-1209

  2. Trazabilidad en el proceso farmacoterapéutico oncológico

    El Farmacéutico. Hospitales, Núm. 205, pp. 15-24

2014

  1. Adequacy of clotting factor in haemophilic patients underwent surgery based on analytical parameters and plasmatic clearance

    Atencion Farmaceutica, Vol. 16, Núm. 2, pp. 110-116